SM-Youtube

Year	Number of Results
2003	1
2004	2
2006	2
2007	2
2009	3
2010	2
2011	1
2012	6
2013	3
2014	2
2016	1
2017	2
2018	2
2019	4
2020	3
2021	4
2022	5
2023	5
2024	5

1

The Significance of Mitochondrial Dysfunction in Cancer.

Luo Y, Ma J, Lu W. Luo Y, et al. Int J Mol Sci. 2020 Aug 5;21(16):5598. doi: 10.3390/ijms21165598. Int J Mol Sci. 2020. PMID: 32764295 Free PMC article. Review.

2

FGF21 in obesity and cancer: New insights.

Lu W, Li X, Luo Y. Lu W, et al. Among authors: luo y. Cancer Lett. 2021 Feb 28;499:5-13. doi: 10.1016/j.canlet.2020.11.026. Epub 2020 Nov 29. Cancer Lett. 2021. PMID: 33264641 Free PMC article. Review.

3

FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.

Song L, Wang L, Hou Y, Zhou J, Chen C, Ye X, Dong W, Gao H, Liu Y, Qiao G, Pan T, Chen Q, Cao Y, Hu F, Rao Z, Chen Y, Han Y, Zheng M, Luo Y, Li X, Chen Y, Huang Z. Song L, et al. Among authors: luo y. Hepatology. 2022 Oct;76(4):1105-1120. doi: 10.1002/hep.32404. Epub 2022 Feb 27. Hepatology. 2022. PMID: 35152446

4

Serum Levels of FGF21 and Prediction of Cardiovascular Events.

Luo Y, Lu W. Luo Y, et al. Cardiology. 2018;139(4):219-221. doi: 10.1159/000486709. Epub 2018 Feb 15. Cardiology. 2018. PMID: 29448256 Free article. No abstract available.

5

Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.

Li X, Lu W, Kharitonenkov A, Luo Y. Li X, et al. Among authors: luo y. J Intern Med. 2024 Mar;295(3):292-312. doi: 10.1111/joim.13767. Epub 2024 Jan 11. J Intern Med. 2024. PMID: 38212977 Review.

6

FGF4 protects the liver from immune-mediated injury by activating CaMKKβ-PINK1 signal pathway to inhibit hepatocellular apoptosis.

Huang Z, Pan T, Xu L, Shi L, Ma X, Zhou L, Wang L, Wang J, Zhu G, Chen D, Song L, Pan X, Wang X, Li X, Luo Y, Chen Y. Huang Z, et al. Among authors: luo y. Acta Pharm Sin B. 2024 Apr;14(4):1605-1623. doi: 10.1016/j.apsb.2023.12.012. Epub 2023 Dec 19. Acta Pharm Sin B. 2024. PMID: 38572102 Free PMC article.

7

Methionine restriction sensitizes cancer cells to immunotherapy.

Lu W, Luo Y. Lu W, et al. Among authors: luo y. Cancer Commun (Lond). 2023 Nov;43(11):1267-1270. doi: 10.1002/cac2.12492. Epub 2023 Oct 6. Cancer Commun (Lond). 2023. PMID: 37803877 Free PMC article. No abstract available.

8

Emerging Structure-Function Paradigm of Endocrine FGFs in Metabolic Diseases.

Luo Y, Ye S, Li X, Lu W. Luo Y, et al. Trends Pharmacol Sci. 2019 Feb;40(2):142-153. doi: 10.1016/j.tips.2018.12.002. Epub 2019 Jan 4. Trends Pharmacol Sci. 2019. PMID: 30616873 Review.

9

Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway.

Zhou C, Pan X, Huang L, Wu T, Zhao T, Qi J, Wu J, Mukondiwa AV, Tang Y, Luo Y, Tu Q, Huang Z, Niu J. Zhou C, et al. Among authors: luo y. Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166870. doi: 10.1016/j.bbadis.2023.166870. Epub 2023 Sep 9. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 37696161

10

Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.

Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W. Luo Y, et al. Gastroenterology. 2019 Nov;157(5):1413-1428.e11. doi: 10.1053/j.gastro.2019.07.030. Epub 2019 Jul 25. Gastroenterology. 2019. PMID: 31352001 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

51 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Search Results

51 results

Results by year